Back to Basics?

Analyst Tim Anderson says that Pfizer could cut back to become strictly a drug discovery firm. To do so, the company would have to strip itself of "divisions accounting for $32 billion of its $67 billion in sales," adds Matthew Herper at Forbes. Anderson says these "extremely bold" moves would be greeted warmly by investors, though Pfizer has not made any commitments one way or the other. Bigger, adds Derek Lowe at In the Pipeline, seems to have turned out to not be better. "It's interesting to see someone at the top, though, who's willing to admit this and to act on it," Lowe adds.